Company intelligence / Profile preview

Endiatx

Hayward, California, United Statesendiatx.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Endiatx has developed PillBot™, a swallowable, remote-controlled robotic capsule that provides real-time video imaging of the stomach. The device aims to replace traditional invasive endoscopy with a minimally invasive alternative. Clinical trials are ongoing and FDA clearance has not yet been obtained as of July 2024. Early demonstrations have shown successful navigation and visualization in live human subjects at major conferences.

Therapeutic areas: Gastroenterology
Modalities: Device (specifically micro robotic capsule endoscopy)
Industry: Medical Imaging

Drug pipeline

1 asset

PillBot

Pre-clinical

Indications: Gastrointestinal disorders

Partnerships

No major pharmaceutical or biotech partnerships disclosed; collaborations with leading gastroenterologists such as Dr. Vivek Kumbhari at Mayo Clinic.

Beyond the preview

Go deeper on Endiatx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endiatx.

Explore the full profile